Low-Density Lipoprotein Test Market 2024 – Growth, Market Size, Analysis, Competitive Landscape | Abbott Laboratories, Qiagen N.V., Randox Laboratories Ltd., Eurofins Scientific SE, Danaher Corporation

Overview and Scope
The low-density lipoprotein (LDL) test refers to a type of blood test that doctors employ to gauge a patient’s bloodstream’s LDL cholesterol levels. LDL testing can assess LDL levels independently or as a component of a lipid panel test. Low-density lipoprotein is an accumulation of cholesterol in the arteries that can contribute to heart attacks and strokes.

Sizing and Forecast
The low-density lipoprotein test market size has grown steadily in recent years. It will grow from $8.11 billion in 2023 to $8.46 billion in 2024 at a compound annual growth rate (CAGR) of 4.3%. The growth in the historic period can be attributed to research advancements in cardiovascular medicine, increased awareness of heart health, shift in treatment paradigms, clinical guidelines and recommendations, focus on preventive healthcare..

The low-density lipoprotein test market size is expected to see steady growth in the next few years. It will grow to $10.24 billion in 2028 at a compound annual growth rate (CAGR) of 4.9%. The growth in the forecast period can be attributed to increasing healthcare expenditure, aging population demographics, rise in cardiovascular disease burden, shift towards personalized medicine, healthcare policy and guidelines.. Major trends in the forecast period include rising cardiovascular disease prevalence, emphasis on preventive healthcare, personalized medicine and treatment, focus on health awareness and education, regulatory guidelines and recommendations..

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/low-density-lipoprotein-test-global-market-report

Segmentation & Regional Insights
The low-density lipoprotein test market covered in this report is segmented –

1) By Product Type: LDL-C, LDL-P, LDL-B, Other Products
2) By Component: Kits, Reagents, Devices, Other Components
3) By Disease Type: Diabetes, Stroke, Atherosclerosis, Obesity, Dyslipidaemia, Carotid Artery Disease, Peripheral Arterial Disease, Angina, Other Disease Types
4) By Distribution Channel: Direct Tenders, Retail
5) By End User: Hospitals, Clinics, Ambulatory Care, Research Laboratory, Other End Users

North America was the largest region in the Low-Density Lipoprotein Test market in 2023. The regions covered in the low-density lipoprotein test market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9395&type=smp

Major Driver Impacting Market Growth
The rise in the prevalence of cardiovascular diseases is expected to propel the growth of the low-density lipoprotein test market going forward. Cardiovascular diseases refer to a type of condition that affects the heart or blood vessels. The LDL test is used to treat cardiovascular diseases by directly measuring low-density lipoprotein levels in the heart. For instance, in October 2022, according to the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, heart disease is the top cause of mortality in the United States for both genders and members of most racial and ethnic groups. Heart disease claimed almost 695,000 people in the United States in 2021, accounting for one in every five deaths. In 2020, the most common type of heart disease, coronary heart disease, killed 375,476 people. Therefore, the rise in the prevalence of cardiovascular diseases is driving the growth of the low-density lipoprotein test market.

Key Industry Players
Major companies operating in the low-density lipoprotein test market are focused on developing innovations, such as homogenous assay, to gain a competitive edge in the market. A homogeneous assay is a type of immunoassay that does not require a separation step to measure the concentration of an analyte. For instance, in May 2021, DiaSys Diagnostic Systems GmbH, a US-based developer of innovative clinical diagnostic equipment, launched LDL-c direct FS, a homogenous assay for directly determining LDL-cholesterol (LDL-C). It is a homogenous block-polymer-based assay for directly determining low-density lipoprotein cholesterol (LDL-c) in serum and plasma. The LDL-c direct FS assay is a fast, accurate, and reliable method for measuring LDL-c levels in patients. The ready-to-use reagent provides extended stability while maintaining a low calibration frequency. It may be utilized with all automated clinical chemical analyzers and exhibits strong compatibility with commercially accessible techniques for measuring low-density lipoprotein.

The low-density lipoprotein test market report table of contents includes:

1. Executive Summary

2. Low-Density Lipoprotein Test Market Characteristics

3. Low-Density Lipoprotein Test Market Trends And Strategies

4. Low-Density Lipoprotein Test Market – Macro Economic Scenario

5. Global Low-Density Lipoprotein Test Market Size and Growth

…..

32. Global Low-Density Lipoprotein Test Market Competitive Benchmarking

33. Global Low-Density Lipoprotein Test Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Low-Density Lipoprotein Test Market

35. Low-Density Lipoprotein Test Market Future Outlook and Potential Analysis

36. Appendix